Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 5. Complementary and Alternative Medicine Treatments

Canadian Journal of Psychiatry

Volumn 61, Issue 9, 2016, Pages 576-587

  Ravindran, Arun V ^a   Balneaves, Lynda G ^a   Faulkner, Guy ^b   Ortiz, Abigail ^c   McIntosh, Diane ^b   Morehouse, Rachel L ^d   Ravindran, Lakshmi ^a   Yatham, Lakshmi N ^b   Kennedy, Sidney H ^a   Lam, Raymond W ^b   MacQueen, Glenda M ^e   Milev, Roumen V ^f   Parikh, Sagar V ^a,g  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Clinical practice guidelines; Complementary and Alternative Medicine; Evidence based medicine; Exercise; Light therapy; Major depressive disorder; Meta analysis; Natural health products; Sleep deprivation; Systematic reviews

Indexed keywords

CROCUS SATIVUS EXTRACT; FOLIC ACID; HYPERICUM PERFORATUM EXTRACT; NATURAL PRODUCT; OMEGA 3 FATTY ACID; PRASTERONE; S ADENOSYLMETHIONINE; TRYPTOPHAN; BIOLOGICAL PRODUCT;

ACNE; ACUPUNCTURE; ADULT; ALTERNATIVE MEDICINE; BREAST CANCER; CANADA; CLINICAL EFFECTIVENESS; CONSENSUS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; EXERCISE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIRSUTISM; HUMAN; HYPERTENSION; HYPOMANIA; INCREASED APPETITE; INSOMNIA; LIVER INJURY; MAJOR DEPRESSION; MANIA; META ANALYSIS (TOPIC); NAUSEA; PHOTOSENSITIVITY; PHOTOTHERAPY; PRACTICE GUIDELINE; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SKIN IRRITATION; SLEEP DEPRIVATION; SYSTEMATIC REVIEW (TOPIC); TACHYCARDIA; TASTE DISORDER; TREATMENT OUTCOME; XEROSTOMIA; YOGA; EVIDENCE BASED MEDICINE; KINESIOTHERAPY; META ANALYSIS; PROCEDURES; STANDARDS;

ACUPUNCTURE THERAPY; BIOLOGICAL PRODUCTS; CANADA; DEPRESSIVE DISORDER, MAJOR; EVIDENCE-BASED MEDICINE; EXERCISE THERAPY; HUMANS; PHOTOTHERAPY; PRACTICE GUIDELINES AS TOPIC; SLEEP DEPRIVATION;

EID: 84986889079     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/0706743716660290     Document Type: Review

References (104)

1. Kennedy SH, Lam RW, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: introduction. J Affect Disord. 2009;11(Suppl 1):S1-S2.
2. National Center for Complementary and Alternative Medicine. What is complementary and alternative medicine? [Internet] 2012 May [cited 2016 June 21]. Available from: https://nccih.nih.gov/sites/nccam.nih.gov/files/D347-05-25-2012.pdf
3. Tindle HA, Davis RB, Phillips RS, et al. Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med. 2005;11:42-49.
4. Solomon D, Adams J. The use of complementary and alternative medicine in adults with depressive disorders: a critical integrative review. J Affect Disord. 2015;197:101-113.
5. Purohit MP, Wells ER, Zafonte RD, et al. Neuropsychiatric symptoms and the use of complementary and alternative medicine. PM R. 2015;5:24-31.
6. Woodward AT, Bullard KM, Taylor RJ, et al. Use of complementary and alternative medicines for mental and substance use disorders: a comparison of African Americans, black Caribbeans, and non-Hispanic whites. Psychiatr Serv. 2009;60:1342-1349.
7. Freeman MP, Fava M, Lake J, et al. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. J Clin Psychiatry. 2010;71:669-681.
8. Qureshi NA, Al-Bedah AM. Mood disorders and complementary and alternative medicine: a literature review. Neuropsychiatr Dis Treat. 2013;9:639-658.
9. Lam RW, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: introduction and methods. Can J Psychiatry. 2016;61(9):506-509.
10. Ravindran AV, Lam RW, Filteau MJ, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: V. Complementary and alternative medicine treatments. J Affect Disord. 2009;117(Suppl 1):S54-S64.
11. Boutron I, Tubach F, Giraudeau B, et al. Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials. J Clin Epidemiol. 2004;57:543-550.
12. Coelhox HF, Pittler MH, Ernst E. An investigation of the contents of complementary and alternative medicine journals. Altern Ther Health Med. 2007;13:40-44.
13. Caulfield T, DeBow S. A systematic review of how homeopathy is represented in conventional and CAM peer reviewed journals. BMC Complement Altern Med. 2005;5:12.
14. Chang HY, Chang HL, Siren B. Exploring the decision to disclose use of natural products among outpatients: a mixed-method study. BMC Complement Altern Med. 2013;13:319.
15. Shelley BM, Sussman AL, Williams RL, et al. 'They don't ask me so I don't tell them': patient-clinician communication about traditional, complementary, and alternative medicine. Ann Fam Med. 2009;7:139-147.
16. Mårtensson B, Pettersson A, Berglund L, et al. Bright white light therapy in depression: a critical review of the evidence. J Affect Disord. 2015;182:1-7.
17. Pail G, Huf W, Pjrek E, et al. Bright-light therapy in the treatment of mood disorders. Neuropsychobiology. 2011;64:152-162.
18. Sohn CH, Lam RW. Update on the biology of seasonal affective disorder. CNS Spectr. 2005;10:635-646.
19. Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14:334-385.
20. Perera S, Eisen R, Bhatt M, et al. Light therapy for nonseasonal depression: systematic review and meta-analysis. B J Psych Open. 2016;2:116-126.
21. Dirmaier J, Steinmann M, Krattenmacher T, et al. Nonpharmacological treatment of depressive disorders: a review of evidence-based treatment options. Rev Recent Clin Trials. 2012;7:141-149.
22. Güleç M. Bright light therapy in treatment of depressive disorders other than seasonal affective disorder. Bull Clin Psychopharm. 2011;21(Suppl 2):S89.
23. Lam RW, Levitt AJ, Levitan RD, et al. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2015;18:1-9.
24. Martiny K, Refsgaard E, Lund V, et al. A 9-week randomized trial comparing a chronotherapeutic intervention (wake and light therapy) to exercise in major depressive disorder patients treated with duloxetine. J Clin Psychiatry. 2012;73:1234-1242.
25. Rohan KJ, Mahon JN, Evans M, et al. Randomized trial of cognitive-behavioral versus light therapy for seasonal affective disorder: acute outcomes. Am J Psychiatry. 2015;172:862-869.
26. Rohan KJ, Meyerhoff J, Ho SY, et al. Outcomes one and two winters following cognitive-behavioral therapy or light therapy for seasonal affective disorder. Am J Psychiatry. 2015 Nov. 5. [Epub ahead of print]
27. Martiny K, Refsgaard E, Lund V, et al. Maintained superiority of chronotherapeutics vs. exercise in a 20-week randomized follow-up trial in major depression. Acta Psychiatr Scand. 2015;131:446-457.
28. Dallaspezia S, Benedetti F. Sleep deprivation therapy for depression. Curr Top Behav Neurosci. 2015;25:483-502.
29. Ravindran AV, da Silva TL. Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: a systematic review. J Affect Disord. 2013;150:707-719.
30. Martiny K, Refsgaard E, Lund V, et al. The day-to-day acute effect of wake therapy in patients with major depression using the HAM-D6 as primary outcome measure: results from a randomised controlled trial. PLoS One. 2013;8:e67264.
31. Moscovici L, Kotler M. A multistage chronobiologic intervention for the treatment of depression: a pilot study. J Affect Disord. 2009;116:201-207.
32. Boyce P, Hopwood M. Manipulating melatonin in managing mood. Acta Psychiatr Scand. 2013;] 444(Suppl 130):16-23.
33. Bunney BG, Bunney WE. Rapid-acting antidepressant strategies: mechanisms of action. Int J Neuropsychopharmacol. 2012;15:695-713.
34. Echizenya M, Suda H, Takeshima M, et al. Total sleep deprivation followed by sleep phase advance and bright light therapy in drug-resistant mood disorders. J Affect Disord. 2013;144:28-33.
35. Sahlem GL, Kalivas B, Fox JB, et al. Adjunctive triple chronotherapy (combined total sleep deprivation, sleep phase advance, and bright light therapy) rapidly improves mood and suicidality in suicidal depressed inpatients: an open label pilot study. J Psychiatry Res. 2014;59:101-107.
36. Dallaspezia S, Benedetti F. Chronobiological therapy for mood disorders. Expert Rev Neurother. 2011;11:961-970.
37. Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. Cochrane Database Syst Rev. 2013;9:CD004366.
38. Stanton R, Reaburn P, Happell B. Is cardiovascular or resistance exercise better to treat patients with depression? A narrative review. Issues Ment Health Nurs. 2013;34:531-538.
39. Nyström MB, Neely G, Hassmén P, et al. Treating major depression with physical activity: a systematic overview with recommendations. Cogn Behav Ther. 2015;44:341-352.
40. Stanton R, Reaburn P. Exercise and the treatment of depression: a review of the exercise program variables. J Sci Med Sport. 2014;17:177-182.
41. Krogh J, Nordentoft M, Sterne JAC, et al. The effect of exercise in clinically depressed adults: systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2011;72:529-538.
42. Josefsson T, Lindwall M, Archer T. Physical exercise intervention in depressive disorders: meta-analysis and systematic review. Scand J Med Sci Sports. 2014;24:259-272.
43. Silveira H, Moraes H, Oliveira N, et al. Physical exercise and clinically depressed patients: a systematic review and metaanalysis. Neuropsychobiology. 2013;67:61-68.
44. Rosenbaum S, Tiedemann A, Sherrington C, et al. Physical activity interventions for people with mental illness: a systematic review and meta-analysis. J Clin Psychiatry. 2014;75:964-974.
45. Danielsson L, Noras AM, WaernM, et al. Exercise in the treatment of major depression: a systematic review grading the quality of evidence. Physiother Theory Pract. 2013;29:573-585.
46. Stubbs B, Vancampfort D, Rosenbaum S, et al. Dropout from exercise randomized controlled trials among people with depression: a meta-analysis and meta regression. J Affect Disord 2015;190:457-466.
47. Mammen G, Faulkner G. Physical activity and the prevention of depression: a systematic review of prospective studies. Am J Prev Med. 2013;45:649-657.
48. Pilkington K, Kirkwood G, Rampes H, et al. Yoga for depression: the research evidence. J Affect Disord. 2005;89:13-24.
49. Cramer H, Lauche R, Langhorst, et al. Yoga for depression: a systematic review and meta-analysis. Depress Anxiety. 2013;11:1068-1083.
50. Brown RP, Gerbarg PL. Sudarshan Kriya Yoga breathing in the treatment of stress, anxiety and depression: Part I-Neurophysiologic model. J Altern Complement Med. 2005;11:189-201.
51. Parikh SV, Quilty LC, Ravitz P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 2.psychological treatments. Can J Psychiatry. 2016;61(9):524-539.
52. Smith CA, Hay PP, Macpherson H. Acupuncture for depression. Cochrane Database Syst Rev. 2010;1:CD004046.
53. Quah-Smith I, Smith C, Crawford JD, et al. Laser acupuncture for depression: a randomized double blind controlled trial using low intensity laser intervention. J Affect Disord. 2013;148:179-187.
54. Wu J, Yeung AS, Schnyer R, et al. Acupuncture for depression: a review of clinical applications. Can J Psychiatry. 2012;57:397-405.
55. Chan YY, Lo WY, Yang SN, et al. The benefit of combined acupuncture and antidepressant medication for depression: a systematic review and meta-analysis. J Affect Disord. 2015;176:106-107.
56. MacPherson H, Richmond S, Bland M, et al. Acupuncture and counseling for depression in primary care: a randomized controlled trial. PLoS Med. 2013;10:e1001518.
57. Zhang ZJ, Chen HY, Yip KC, et al. The effectiveness and safety of acupuncture therapy in depressive disorders: systematic review and meta-analysis. J Affect Disord. 2010;124:9-21.
58. Sarris J, Panossian A, Schweitzer I, et al. Herbal medicine for depression, anxiety, and insomnia: a review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol. 2011;21:841-860.
59. Butterweck V, Schmidt M. The mechanisms of action of St. John's wort: an update. Wien Med Wochenschr. 2015;165:229-235.
60. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a metaanalysis. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:118-127.
61. Carpenter DJ. St. John's wort and S-adenosyl methionine as "natural" alternatives to conventional antidepressants in the era of the suicidality boxed warning: what is the evidence for clinically relevant benefit? Altern Med Rev. 2011;16:17-39.
62. Sarris J, Fava M, Schweitzer I, et al. St. John's wort (Hypericum perforatum) versus sertraline and placebo in major depressive disorder: continuation data from a 26-week RCT. Pharmacopsychiatry. 2012;45:275-278.
63. Mannel M, Kuhn U, Schmidt U, et al. St. John's wort extract LI160 for the treatment of depression with atypical features - a double-blind, randomized, and placebo-controlled trial. J Psychiatr Res. 2010;44:760-767.
64. Kasper S, Gastpar M, Möller HJ, et al. Better tolerability of St. John'swort extractWS5570 compared to treatment withSSRIs: a renanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol. 2010;25:204-213.
65. Brattström A. Long-term effects of St. John's wort (Hypericum perforatum) treatment: a 1-year safety study in mild to moderate depression. Phytomedicine. 2009;16:277-283.
66. Sarris J, Kavanagh DJ. Kava and St. John's wort: current evidence for use in mood and anxiety disorders. J Altern Complement Med. 2009;15:827-836.
67. Borrelli F, Izzo AA. Herb-drug interactions with St. John's wort (Hypericum perforatum): an update on clinical observations). AAPS J. 2009;11:710-727.
68. Natural Medicines Comprehensive Database. St. John's wort monograph [Internet]. 2015 [cited 2015 Oct. 27]. Available from: http://naturaldatabase.therapeuticresearch.com/nd/Search.aspx?cs=CEPDA&s=ND&pt=100&id=329&ds= interdrug&name=St+John's+Wort+ (ST.+JOHN'S+ WORT)
69. Sarris J, Kavanagh DJ, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. J Psychiatr Res. 2010;44:32-41.
70. Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry. 2012;17:1272-1282.
71. Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One. 2014;9:e96905.
72. Appleton KM, Sallis HM, Perry R, et al. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev. 2015;11:CD004692.
73. Sublette ME, Ellis SP, Geant AL, et al. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. 2011;72:1577-1584.
74. Rocha Araujo DM, Vilarim MM, Nardi AE. What is the effectiveness of the use of polyunsaturated fatty acid omega-3 in the treatment of depression? Expert Rev Neurother. 2010;10:1117-1129.
75. Lespérance F, Frasure-Smith N, St-André E, et al. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry. 2011;72:1054-1062.
76. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006;67:1954-1967.
77. Osher Y, Belmaker RH, Nemets B. Clinical trials of PUFAs in depression: state of the art. World J Biol Psychiatry. 2006;7:223-230.
78. Parker G, Gibson NA, Brotchie H, et al. Omega-3 fatty acids and mood disorders. Am J Psychiatry. 2006;163:969-978.
79. Levkovitz Y, Alpert JE, Brintz CE, et al. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Eur Psychiatry. 2012;27:518-521.
80. Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr Psychiatry Rep. 2003;5:460-466.
81. De Berardis D, Orsolini L, Serroni N, et al. A comprehensive review on the efficacy of S-adenosyl-L-methionine in major depressive disorder. CNS Neurol Disord Drug Targets. 2016;15:35-44.
82. Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009;94:3676-3681.
83. Hu Q, Zhang SY, Liu F, et al. Clinical significance of decreased protein expression of dehydroepiandrosterone sulfate in the development of depression: a meta-analysis. J Affect Disord. 2015;174:416-423.
84. Natural Medicines Comprehensive Database. DHEA monograph [Internet]. 2015 [cited 2015 Oct. 27]. Available from: http://naturaldatabase.therapeuticresearch.com/nd/Search. aspx?cs=CEPDA&s=ND&pt=100&id=331&ds=adverse &name=DHEA&searchid53902584
85. Shaw K, Turner J, Del Mar. C. Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. Aust N Z J Psychiatry. 2002;36:488-491.
86. Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther. 2006;109:325-338.
87. Jangid P, Malik P, Singh P, et al. Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode. Asian J Psychiatr. 2013;6:29-34.
88. Bezchlibnyk-Butler KZ, Jeffries JJ, Virani AS. Clinical handbook of psychotropic drugs. 17th ed. New York (NY): Hogrefe and Huber; 2007.
89. Almeida OP, Ford AH, Flicker L. Systematic review and meta-analysis of randomized placebo-controlled trials of folate and vitamin B12 for depression. Int Psychogeriatr. 2015;27:727-737.
90. Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry. 2009;70(Suppl 5):12-17.
91. Papakostas GI, Cassiello CF, Iovieno N. Folates and S-adenosylmethionine for major depressive disorder. Can J Psychiatry. 2012;57:406-413.
92. Ginsberg LD, Oubre AY, Daoud YA. L-methylfolate plus SSRIS or SNRI from treatment initiation compared to SSRI or SNRI monotherapy in a major depressive episode. Innov Clin Neurosci. 2011;8:19-28.
93. Mukai T, Kishi T, Matsuda Y, et al. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol. 2014;29:55-63.
94. Wang SM, Han C, Lee SJ, et al. A review of current evidence for acetyl-l-carnitine in the treatment of depression. J Psychiatr Res. 2014;53:30-37.
95. Christodoulou E, Kadoglou NP, Kostomitsopoulos N, et al. Saffron: a natural product with potential pharmaceutical applications. J Pharm Pharmacol. 2015 Aug. 14. [Epub ahead of print]
96. Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Hum Psychopharmacol. 2014;29:517-527.
97. Hausenblas HA, Saha D, Dubyak PJ, et al. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med. 2013;11:377-383.
98. Dwyer AV, Whitten DL, Hawrelak JA. Herbal medicines, other than St. John's wort, in the treatment of depression: a systematic review. Altern Med Rev. 2011;16:40-49.
99. Hausenblas HA, Heekin K, Mutchie HL, et al. A systematic review of randomized controlled trials examining the effectiveness of saffron (Crocus sativus L.) on psychological and behavioral outcomes. J Integr Med. 2015;13:231-240.
100. Mills S, Bone K. The essential guide to herbal safety. Maryland Heights (MO): Elsevier; 2005.
101. Nikfarjam M, Parvin N, Assarzadegan N, et al. The effects of lavandula angustifolia mill infusion on depression in patients using citalopram: a comparison study. Iran Red Crescent Med J. 2013;15:734-739.
102. Iovieno N, Dalton ED, Fava M, et al. Second-tier natural antidepressants: review and critique. J Affect Disord. 2011;130:343-357.
103. Mao JJ, Xie SX, Zee J, et al. Rhodiola rosea vs.sertraline for major depressive disorder: a randomized placebo-controlled trial. Phytomedicine. 2015;22:394-399.
104. Panossian A, Hovhannisyan A, Abrahamyan H, et al. Pharmacokinetic and pharmacodynamic study of interaction of Rhodiola rosea SHR-5 extract with warfarin and theophylline in rats. Phytother Res. 2009;23:351-357.